34
total announcements
532321.BO · 15 min delayed
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has released an investor presentation for Q1 FY27, showing a 2% growth in total revenues. The presentation highlights the company's R&D and operations.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd announced unaudited financial results for the quarter ended June 30, 2026, with the company's management and board of directors approving the results based on the recommendations of the audit committee.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has announced unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at INR 27,235 million, a decrease from INR 35,646 million in the previous quarter. The company's management has approved the results, and the limited review reports of Deloitte Haskins & Sells LLP have been certified.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has launched REVAHALE, India's first once-daily nebulised LAMA for COPD, addressing unmet needs in disease management.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd will participate in the Motilal Oswal 22nd Annual Global Investor Conference on August 18, 2026.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Indocyanine Green for Injection, a sterile lyophilised powder for reconstitution, with 180-Days CGT exclusivity.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has published a notice in the Financial Express newspaper regarding the loss of share certificates held by two shareholders. The company has requested that if no objections are received within 7 days, duplicate share certificates will be issued to the affected shareholders.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd will participate in the Emkay Confluence 2026 investor conference on August 13, 2026.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd is participating in the Equirus Annual India Conference 2026 on August 13, 2026, as an investor conference.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has received an Establishment Inspection Report (EIR) from the USFDA for its injectable facility at Zydus Biotech Park, Ahmedabad, with a Voluntary Action Indicated (VAI) classification following a GMP surveillance inspection from April 27 to May 5, 2026.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has announced the details of its Q1 FY27 post-results earning call, scheduled for August 11, 2026, at 4:00 p.m. IST. The call will be hosted by Dr. Sharvil Patel, Managing Director, and will be available on the company's website and through a pre-registered link.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has received an order from the Office of the Superintendent of Stamps, Gandhinagar, Gujarat, regarding the acquisition of assets from Sterling Biotech Limited. The authority has determined the market value of the transferred property at ₹ 1,542.60 million and ordered recovery of alleged deficient stamp duty of ₹ 53.47 million along with penalties aggregating to ₹ 55.07 million, resulting in a total demand of ₹ 108.54 million.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has temporarily suspended some operations at its Ahmedabad facilities due to torrential rain and water logging, but has resumed operations as the weather improves.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd has received approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR. The trial will evaluate the efficacy and safety of Desidustat oral tablets in treating anemia. The US FDA has granted Orphan Drug Designation (ODD) to Zydus' Desidustat for treating two rare blood disorders: Sickle Cell Disease (SCD) and beta-thalassemia.